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Background and Purpose: Dyspnea is an important symptomatic endpoint for
assessment of radiation-induced lung injury (RILI) following radical radiotherapy in
locally advanced disease, which remains the mainstay of treatment at the time of
significant advances in therapy including combination treatments with immunotherapy
and chemotherapy and the use of local ablative radiotherapy techniques. We investigated
the relationship between dose-volume parameters and subjective changes in dyspnea as
a measure of RILI and the relationship to spirometry.
Material and Methods: Eighty patients receiving radical radiotherapy for non-small cell
lung cancer were prospectively assessed for dyspnea using two patient-completed tools:
EORTC QLQ-LC13 dyspnea quality of life assessment and dyspnea visual analogue scale
(VAS). Global quality of life, spirometry and radiation pneumonitis grade were also
assessed. Comparisons were made with lung dose-volume parameters.
Results: The median survival of the cohort was 26 months. In the evaluable group of 59
patients there were positive correlations between lung dose-volume parameters and a
change in dyspnea quality of life scale at 3 months (V30 p=0.017; V40 p=0.026; V50
p=0.049; mean lung dose p=0.05), and a change in dyspnea VAS at 6 months (V30
p=0.05; V40 p=0.026; V50 p=0.028) after radiotherapy. Lung dose-volume parameters
predicted a 10% increase in dyspnea quality of life score at 3 months (V40; p=0.041, V50;
p=0.037) and dyspnea VAS score at 6 months (V40; p=0.027) post-treatment.
Conclusions:Worsening of dyspnea is an important symptom of RILI. We demonstrate a
relationship between lung dose-volume parameters and a 10% worsening of subjectiveDecember 2020 | Volume 10 | Article 5945901
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Frontiers in Oncology | www.frontiersin.orgdyspnea scores. Our findings support the use of subjective dyspnea tools in future studies
on radiation-induced lung toxicity, particularly at doses below conventional lung radiation
tolerance limits.Keywords: non-small cell lung cancer, radiotherapy, dyspnea, dose-volume parameters, radiation-induced
lung injuryINTRODUCTION
Radical radiotherapy (RT), with or without chemotherapy has an
established role as an alternative to surgery in medically
inoperable, localized and locally advanced non-small cell lung
cancer (NSCLC) (1, 2). In particular, chemoradiation represents
the standard of care for locally advanced disease (3–5). The
disappointing survival rates following radical conventionally
fractionated RT have been the impetus behind application of
advanced RT techniques with the aim of increasing radiation
dose intensity without additional toxicity (6–9).
Radiation-induced lung injury (RILI) remains a significant
limiting factor to dose escalation. Knowledge of the effect of
radiation on lung is imperative for optimization and comparison
of the relative merits of different RT plans. The risk of radiation
pneumonitis (RP), an interstitial pulmonary inflammatory
process usually developing within 6 months of RT, is the
predominant endpoint used to quantify RILI, forming the basis
of recommended RT dose-volume constraints obtained by lung
dose volume histogram (DVH) in conventional RT (10).
However, the grading of RP is challenging as the most
frequently used scoring systems, including the Common
Terminology Criteria for Adverse Events (CTCAE) and the
Radiation Therapy Oncology Group (RTOG) system, have a
small number of broad categories combining symptomatic,
functional, and radiological criteria in addition to indication of
medical intervention. In addition, the incidence of clinically
significant RP is low and therefore, it is not discriminatory at
doses below conventional tolerance defined by incidence of RP.
Arguably, the most clinically relevant endpoint for patients is the
worsening of symptoms, particularly dyspnea. A more
discriminating measure of the effect of radiation on dyspnea may
be useful for weighing up the potential risks and benefits of a RT
plan at doses below conventional tolerance defined by the incidence
of RP. We carried out an explorative, prospective assessment of
dyspnea based on the hypothesis that RILI below conventional
tolerance may be detected and quantifiable where dyspnea
assessment may offer a more discriminatory and objective measure.MATERIALS AND METHODS
Patient Population
Between February 2003 and January 2011, patients were invited
to participate in a prospective observational study following
approval by the institution’s Committee for Clinical Research
and Local Research Ethics Committee. The trial was conducted2
in accordance with European Union guidelines for Good Clinical
Practice and signed informed consent was obtained from
participants. All patients scheduled to receive radical RT to a
dose of 64 Gray (Gy) in 32 daily fractions were eligible for study
entry if they fulfilled the following criteria: histological or
radiological diagnosis of localized medically inoperable or
unresectable locally advanced NSCLC (AJCC 6th edition stages
I-III, excluding T4 lesions associated with pleural effusion),
baseline forced expiratory volume in 1 s (FEV1) greater than
40% of predicted normal value and World Health Organization
(WHO) performance status 0-2.
Radiotherapy Planning and Delivery
A planning helical computed tomography (CT) scan of the
thorax was acquired with the patient positioned on a chest
board either in free breathing or breath-hold using the active
breathing control (ABC) device with 2.5–3 mm slice thickness
(11, 12). RT planning was performed using the Pinnacle3
planning software (Philips Medical Systems Madison, WI). The
extent of the gross tumor volume (GTV) was defined using CT
lung windows (Width=1600, Length=-300) with reference to
diagnostic imaging. The clinical target volume (CTV) was
considered the same as the GTV. In patients treated in free
breathing, a margin of 1.5 cm was added cranio-caudally with
axially 1 cm for central disease and 1.5 cm for peripheral disease
added to the CTV to create the planning target volume (PTV). In
patients treated with ABC, an isotropic margin of 1 cm was
added from CTV to PTV. Conformal plans were created to
ensure adequate coverage of the PTV in accordance with
International Commission on Radiation Units (IRCU) 50 and
62 recommendations, whilst maintaining the constraints for
organs at risk. Treatment was delivered in a single phase to a
dose of 64 Gy in 32 daily fractions prescribed to the 100%
isocenter using a linear accelerator (Elekta, Crawley, UK).
Radiotherapy Lung DVH Parameters
Both lungs were considered together as a single paired organ and
contoured on the planning scan using CT lung windows. Care
was taken to ensure inclusion of the whole lung tissue from
apices to bases including regions of collapse or consolidation.
The extent of the GTV/CTV, trachea and proximal bronchial
tree were excluded from the volume. The total mean lung dose
(MLD) was recorded for each patient in addition to the
percentage of the total lung volume at threshold doses of
radiation in Gy (Vdose) ranging from 20 Gy to 60 Gy in 10 Gy
increments (V20, V30, V40, V50, V60). All plans met the dose
constraints of a V20 ≤30% and a MLD of ≤18 Gy.December 2020 | Volume 10 | Article 594590
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Assessments and Dyspnea Scales
Dyspnea, pneumonitis, spirometry and quality of life (QoL) were
prospectively assessed at baseline prior to treatment, at 3, 6, 9,
and 12 months after completion of RT and then 6 monthly until
disease progression or death. Patients were imaged with chest
radiograph or CT scan at follow-up time-points. At baseline
patients were asked to complete the Adult Comorbidity
Evaluation 27 questionnaire (ACE-27) (13). At each scheduled
study appointment patients were assessed clinically and the
physician-scored pneumonitis grade (CTCAE) was recorded
(14). Patients were asked to complete the European
Organisation for Research and Treatment of Cancer (EORTC)
QoL questionnaire including the lung module (QLQ-LC13) (15,
16). Dyspnea was assessed using the breathlessness section of
QLQ-LC13 and from patients’ marking the dyspnea visual
analogue scale (VAS), a 100 mm long vertical line, to indicate
their degree of breathlessness (17). Each VAS was separately
recorded without reference to previous reading. Pulmonary
function tests (PFT) consisted in FEV1 and forced vital
capacity (FVC) measured using an Alpha III spirometer
(Vitalograph, Lenexa, KS) and were recorded as the percentage
of the predicted value. Ventilation parameters were chosen for
correlative analysis because strictly representative for respiratory
function and capacity, unlike perfusion parameters possibly
affected by confounding factors, such as cardiac and/or
hematological comorbidities.
Statistical Analysis
A sample size of at least 30 lung cancer patients was arbitrary
defined, since this was an explorative, prospective study and no
similar study designs to compare with for accrual evaluation have
ever been reported in literature. Statistical analysis will eventually
be descriptive for future findings and data integration.
Survival analysis from the start of radiation treatment was
performed using the Kaplan-Meier method. As the primary
objective was to assess changes in dyspnea and other measures
of lung function due to radiation, patients with progressive
disease were censored for dyspnea assessment at the time of
disease progression. Median follow-up, progression free survival
(PFS) and overall survival (OS) were calculated with 95%
confidence intervals (CI).
Data were taken from the 3 QoL questions related to
breathlessness (Table 1) and the calculated dyspnea QoL score
was normalized to a 100 point scale (16). The dyspnea VAS wasFrontiers in Oncology | www.frontiersin.org 3assessed and attributed a score from 0 to 10 to the nearest
millimeter. The global QoL score was calculated from 0 to 100.
The pneumonitis grade and the percentage of predicted normal
values for FEV1 and FVC were documented.
Changes in dyspnea QoL, dyspnea VAS, global QoL, FEV1,
and FVC from the baseline pre-RT measurement were detected
for individual patients at each post-irradiation time-point. A
positive change indicated a worsening of dyspnea QoL, dyspnea
VAS and global QoL and an improvement in FEV1 and FVC.
Comparisons between the mean changes and the corresponding
baseline values for the cohort were performed with 95% CI at
each post-RT time-point and correlations with lung DVH
parameters at 3, 6, and 12 months post-RT were assessed using
rank correlation coefficients. The association between the rate of
≥ grade 2 RP at 3 months after RT and lung DVH parameters
was calculated using a rank correlation coefficient. The rate of RP
at other time-points was considered too much low for further
correlation assessments.
Where a significant correlation at the 5% level was observed
between lung DVH parameters and changes from baseline post-
RT, the Mann Whitney test was performed to test for correlation
of lung DVH parameters with a clinically relevant worsening of
dyspnea or pulmonary function. For the purposes of statistical
analysis, a clinically relevant worsening was defined as follows:
10% increase in dyspnea QoL compared to baseline, 10%
increase in dyspnea VAS compared to baseline, and 10%
decrease in FEV1 or FVC compared to baseline. Exploratory
receiver operator curve (ROC) analyses were also carried out to
assess for an optimal cut-off to predict worsening of dyspnea or
pulmonary function following treatment.RESULTS
Patient Population, Follow-Up and Disease
Outcome
Eighty consecutive patients during the study period fitted the
selection criteria and accepted to participate to the study. Among
these, 21 patients were excluded from further analysis: five had
missing pre-RT dyspnea assessment, one did not complete RT
due to pulmonary embolism, eight had missing 3-month post-
RT dyspnea assessment and seven developed disease progression
prior to 3-month post-RT assessment. Data from the remaining
59 patients were analyzed for the study purpose. The
characteristics of the population in study are summarized in
Table 2. In particular, 34 (57.6%) patients suffered from cardiac
and/or hematological comorbidities, and 54 (91.5%) of them
reported smoke habit.
With a median follow-up of 20 months (range 0 to 78), the
median progression free survival was 16 months (95% CI: 10–23)
and the median overall survival was 26 months (95% CI: 14–38)
(Figure 1).
Baseline Measurements and Compliance
The mean baseline dyspnea QoL, dyspnea VAS, global QoL, FEV1
and FVC and lung dose-volume data for the cohort are summarizedTABLE 1 | EORTC QLQ-LC13 dyspnea QoL assessment.








Were you short of breath when you
rested?
1 2 3 4
Were you short of breath when you
walked?
1 2 3 4
Were you short of breath when you
climbed stairs?
1 2 3 4December 2020 | Volume 10 | Article 594590
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3 months post-RT. Taking withdrawal of patients from further
follow-up due to disease progression and death into account, 2/48
(4%), 16/39 (41%), 1/35 (3%) had missing follow-up assessments at
6, 9, and 12 months, respectively, with no missing assessments but
few surviving patients at 18 months post-RT excluded from furtherFrontiers in Oncology | www.frontiersin.org 4analysis, data attributable to the prognosis of the percentage of
patients with IIIA and IIIB disease stage.
Change in Dyspnea Quality of Life,
Dyspnea VAS, Global Quality of Life, FEV 1
and FVC from Baseline, and Rate of
Radiation Pneumonitis
The mean dyspnea QoL score of the cohort increased by 4 (95%
CI: -2–10) at 3 months after irradiation. Twenty-nine patients
(49%) had worse dyspnea QoL with a mean increase in score of
22 (95% CI: 17–27); 20 patients (34%) had improved dyspnea
QoL with a mean decrease in score of 20 (95% CI: 15–26) and 10
patients (17%) had no change in QoL score. The mean change
from baseline at follow-up time-points is displayed in Table 4.
Changes in dyspnea QoL from baseline at different time-points
by classifying patients as those who initially improved, remained
stable, or worsened between baseline and 3 months post-RT are
displayed in Figure 2. The mean change in dyspnea VAS, global
QoL, FEV1, and FVC from baseline at the follow up time-points
is reported in Table 4. At 3 months post-RT eight (14%), twoA B
FIGURE 1 | (A) PFS and (B) OS in a cohort of 80 patients treated with radical RT.TABLE 3 | Baseline assessment and normal lung DVH data.
Measurement Mean 95% CI
Dyspnea QoL (n=59) 26 21–31
Dyspnea VAS (n=59) 2.2 1.5–2.8
Global QoL (n=58) 67 63–72
FEV1% of predicted (n=56) 69 64–74
FVC % of predicted (n=55) 86 80–91
MLD (Gy) (n=59) 12 11–13
V20 (%) (n=59) 23 20–26
V30 (%) (n=59) 18 15–21
V40 (%) (n=59) 13 11–16
V50 (%) (n=59) 9 7–12
V60 (%) (n=59) 6 4–9December 2020 | Volume 10 | ArticleQoL, quality of life; VAS, visual analogue scale; FEV1, forced expiratory volume in 1 s; FVC,
forced vital capacity; MLD, mean lung dose; Vdose, percentage of the total lung volume at
threshold doses of radiation in Gy.TABLE 2 | Patient and disease characteristics.

















Never smoker or ex-smoker 5 8
Disease characteristics
Histological diagnosis









Neoadjuvant chemotherapy 24 41
Prior lobectomy 3 5WHO, World Health Organization; AJCC, American Joint Committee on Cancer.594590
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respectively. At 6 months after the treatment, three (7%), one
(3%), and one (3%) patients had grade 1, grade 2, and grade 3
RP, respectively.
Relationship Between Lung DVH and
Measures of Lung Function
Table 5 shows the relationship between dyspnea and lung
function measures including dyspnea QoL, dyspnea VAS, FEV1,
FVC, and incidence of RP. Change in dyspnea QoL score at 3
months correlated with the lung V30, V40, V50, andMLD (p=0.017,
p=0.026, p=0.049, and p=0.05, respectively). There was no
significant correlation between lung DVH parameters and
change in dyspnea VAS, global QoL, FEV1, FVC, and rate of ≥
grade 2 RP at 3 months. Change in dyspnea VAS score at 6
months correlated with the lung V30, V40, and V50 (p=0.05,
p=0.026 and p=0.028, respectively). No significant correlation
between lung DVH parameters and change in dyspnea QoL,
global QoL, FEV1 or FVC was demonstrated at 6 months. At 12
months there was a significant negative correlation between the
change in FVC and the lung V40 and V60 (p=0.043 and p=0.046,
respectively) and between the change in FEV1 and lung V40, V50,
and V60 (p=0.016, p=0.011, and p=0.005, respectively).Frontiers in Oncology | www.frontiersin.org 5ROC Analysis for Lung Damage Post-
Radiotherapy
Lung damage defined by a 10% increase in dyspnea QoL score at
3 months correlated with the lung V40 and V50 with an area
under the curve (AUC) of 0.66 (p=0.041) and 0.66 (p=0.037),
respectively (Figure 3). Lung damage defined by a 10% increase
in dyspnea VAS score at 6 months correlated to the lung V40 with
an AUC of 0.69 (p=0.027) (Figure 3). A cut off of 11% for the V40
was associated with a sensitivity of 76% and a specificity of 53%
for predicting worsening of dyspnea by a 10% increase in
dyspnea QoL score at 3 months, and a sensitivity of 83% and a
specificity of 61% by a 10% increase in dyspnea VAS score at 6
months post-RT. ROC analysis demonstrated that no DVH
parameter significantly predicted clinically relevant lung
damage defined by a 10% decrease in FVC or FEV1 (% of
predicted) at 12 months post-RT compared to baseline.DISCUSSION
Worsening of dyspnea is a characteristic feature of clinically
relevant RILI (18). Our study aimed to prospectively evaluateTABLE 4 | Mean change from baseline of dyspnea QoL, dyspnea VAS, global QoL, and percentage of predicted FEV1 and FVC at time-points post-RT with 95% CI in
parentheses.
Time post-RT (months) Mean change in % dyspnea scores (range)
3 6 9 12 18
Dyspnea QoL score 4 (-2 to 10) 7 (0 to15) 2 (-4 to 8) 11 (3 to 20) 15 (5 to 26)
Dyspnea VAS score 1.0 (0.2 to 1.8) 1.7 (0.8 to 2.7) 1.3 (0.3 to 2.3) 1.7 (0.5 to 2.8) 2.1 (0.8 to 3.5)
Global QoL score 1 (-5 to 7) -6 (-14 to 3) -10 (-21 to 2) -8 (-16 to 0) -5 (-16 to 6)
% of predicted FEV1 2 (-1 to 4) 1 (-3 to 6) 2 (-5 to 8) 0 (-5 to 6) 2 (-4 to 8)
% of predicted FVC 2 (-3 to 8) -2 (-6 to 2) 3 (-7 to 12) -1 (-7 to 6) 2 (-6 to 9)December 2020 | Volume 10 |A B C
FIGURE 2 | Change in dyspnea QoL from baseline at different time-points by classifying patients as those who (A) initially improved (QoL score decreased: 20/59;
34%), (B) remained stable (10/59; 17%), or (C) initially worsened (QoL score increased: 29/59; 49%) between baseline and 3 months post-RT.Article 594590
Sardaro et al. Dyspnea Scoring in Lung Cancer Radiotherapysubjective dyspnea changes following radical RT for NSCLC as a
measure of potential lung toxicity when treating to disease below
radiation tolerance of the lung.
The study demonstrated a significant correlation between
lung DVH parameters and change in dyspnea post-RT using two
different patient-completed dyspnea tools. Three months post-
RT, a change in dyspnea QoL score significantly correlated with
lung DVH parameters (V30 p=0.017; V40 p=0.026; V50 p=0.049;
MLD p=0.05). Six months post-RT, a change in dyspnea VAS
score significantly correlated with lung DVH parameters (V30
p=0.05; V40 p=0.026; V50 p=0.028). Lung DVH parameters were
significantly predictive for a 10% increase in dyspnea QoL score 3
months post-RT (V40; p=0.041, V50; p=0.037) and dyspnea VAS
score 6 months after the treatment (V40; p=0.027), respectively.
The observed rate of ≥ grade 2 RP at 3 and 6 months post-RT
was low (6%) with no correlation observed between rate of ≥ gradeFrontiers in Oncology | www.frontiersin.org 62 RP and lung DVH parameters. This low rate of RP is to be
expected given that the lung dose-volume constraints were met for
all RT plans. Despite a significant negative correlation at 12months
between any change in the percentage of predicted FVC and lung
V40 and V60, respectively, and between any change in percentage of
predicted FEV1 and lung V40, V50, and V60, respectively, no lung
DVH parameters were significant predictors of a clinically relevant
worsening of FVC or FEV1, defined in this study by a 10%
reduction in percentage of predicted values.
Dyspnea in patients with NSCLC is multi-factorial and is
affected by respiratory and cardiac comorbidity (18, 19). While
dyspnea is the predominant symptom in classical RP, the clinical
diagnosis of RP is challenging due to confounding cardio-
respiratory conditions affecting the lung cancer patient
population (20). In addition, baseline respiratory function/









Change in FVCas % of
predicted
Change in FEV1as %
of predicted
Rate of ≥ grade 2 RP
3m 6m 12m 3m 6m 12m 3m 6m 12m 3m 6m 12m 3m 6m 12m 3m
N 59 44 30 59 45 33 57 44 32 52 38 29 52 39 29 4
V20 Co 0.22 0.15 0.00 0.18 0.18 0.17 -0.12 -0.06 0.27 -0.09 -0.23 -0.24 -0.05 -0.15 -0.15 0.45
Sig 0.088 0.340 0.995 0.180 0.247 0.335 0.378 0.688 0.139 0.540 0.169 0.205 0.745 0.373 0.432 0.553
V30 Co 0.31 0.27 0.19 0.21 0.29 0.22 -0.20 -0.15 -0.03 -0.06 -0.23 -0.31 -0.08 -0.19 -0.29 0.89
Sig 0.017 0.074 0.327 0.107 0.050 0.220 0.145 0.336 0.879 0.659 0.172 0.097 0.585 0.247 0.129 0.106
V40 Co 0.29 0.20 0.18 0.17 0.33 0.31 -0.17 -0.12 -0.05 0.00 -0.13 -0.38 -0.85 -0.17 -0.45 0.89
Sig 0.026 0.184 0.351 0.207 0.026 0.080 0.194 0.438 0.798 0.979 0.442 0.043 0.549 0.309 0.016 0.106
V50 Co 0.26 0.232 0.12 0.13 0.33 0.22 -0.17 -0.10 0.05 0.06 -0.14 -0.35 -0.05 -0.22 -0.47 0.45
Sig 0.049 0.13 0.539 0.335 0.028 0.229 0.217 0.530 0.807 0.669 0.400 0.062 0.728 0.185 0.011 0.553
V60 Co 0.13 0.15 -0.02 0.11 0.28 0.17 -0.08 0.02 0.14 0.13 -0.08 -0.37 -0.04 -0.27 -0.50 0.00
Sig 0.327 0.333 0.915 0.402 0.060 0.348 0.549 0.879 0.452 0.346 0.625 0.046 0.799 0.099 0.005 1.000
MLD Co 0.26 0.06 -0.22 0.05 0.11 -0.03 -0.14 -0.01 0.16 -0.14 -0.20 -0.34 -0.22 -0.09 -0.23 0.45
Sig 0.050 0.688 0.240 0.717 0.476 0.858 0.285 0.939 0.396 0.342 0.234 0.069 0.123 0.590 0.222 0.553December 2020 | Volum, months; N, number of patients; Co, correlation coefficient; Sig, 2-tailed significance.
Significant correlations shown in bold.A B
FIGURE 3 | Receiver Operator Curve (A) for 10-point change in dyspnea QoL between baseline and 3 months post-RT (B) for 1-point change in dyspnea VAS
between baseline and 6 months post-RT.me 10 | Article 594590
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objective tests. Nevertheless, it is of primary importance to the
patient and in the absence of RP may provide a more sensitive
measure of small changes to lung function and arguably a more
appropriate measure for monitoring the patterns and severity of
dyspnea over time. This study explored the relationship between
lung dose-volume information and patient-recorded changes in
dyspnea following irradiation. Measurement of relative dyspnea
compared to baseline pre-RT values was performed to account
for comorbidities as a confounding factor. However, given the
complexity of dyspnea as a symptom, two tools were used to
permit both a unidimensional dyspnea assessment with the VAS
(17) and a lung cancer specific dyspnea assessment tool derived
from the EORTC QOL questionnaire (15, 16). Such an approach
to assessment of dyspnea had been suggested in a systematic
review of the available tools (22) and a 10% change from baseline
values is a reasonable measure of a clinically meaningful change
(23). The dyspnea scales used in this study were demonstrated as
a valid and reliable tool in a range of cancer patient populations,
including lung cancer patients, and confirmed to reflect the
common symptoms and treatment-related toxicities underlying
radio(chemo)therapy (24). Another limitation of the study is the
multiple testing in a small number of patients and the associated
increased potential for Type I error in the results. Therefore, our
results require validation in a larger cohort of patients.
Advances in planning software and delivery techniques
permitted increasing flexibility when adjusting RT plans to spare
normal tissue while maintaining target coverage. Distilling lung 3-
dimensional dose-volume distribution data down to a threshold
metric for risk of RILI produce a range of thresholds for various
metrics in the RP literature (25–38). This is likely to be due to the
gradual increase in lung damage with radiation dose (18). However,
recommended thresholds for MLD and lung V20 with conventional
fractionation remain widely used as normal tissue dose-constraints
and are considered useful to aid assessment and optimization of
different RT plans (10, 39). In this series, we recorded MLD 11% to
13%Gy and V20 20% to 26%, in line with the accepted thresholds to
minimize the risk of RILI (40). While the relatively small numbers
in this study limited the statistical power of the results, ROC curve
analyses suggested that the percentage volume of lung receiving 40
Gy (V40) may be predictive for an increase in subjective dyspnea
following conventionally fractionated RT. A lung V40 threshold of
11% may be a useful additional constraint and warrants validation
in a larger cohort of patients.
We report the first radiotherapy study to describe the
relationship between lung DVH parameters and self-assessed
dyspnea scores. There have been studies of physician scored
dyspnea which is recognized to suffer from investigator bias.
Lung DVH parameters have shown no correlation with a change
in physician-scored dyspnea score in stage I NSCLC patients
receiving stereotactic RT (41). The evolution of dyspnea
following radical RT for stage I-III NSCLC has also been
studied in 197 patients using the physician-scored CTCAE
classification (dyspnea grades 0–4) with worsening dyspnea in
17% to 27% of patients. The investigators highlighted the need
for assessing dyspnea at more than one time-point post-RT (42).Frontiers in Oncology | www.frontiersin.org 7To date, radiobiological parameters, rather than subjective
dyspnea tools, have gained increasing interest in preventing RILI
for thoracic irradiation. Recent publications argue in favor of
NTCP model as a possible way to optimize treatment plans
according to the probability of RP (18), and a multinomial NTCP
has been proposed as possibly predictive for dyspnea grade with
high accuracy (43). The need for intensification of local
treatment to achieve better local control and improve survival
rates for NSCLC without additional toxicity has also given rise to
several, promising, dose escalation studies in United Kingdom,
based on prespecified and mean lung dose constraints to increase
tumor control probability without worsening normal tissue
complication probability (NTCP) (44–49).
Radiotherapy dose-independent clinical factors impact on the
risk of RILI (18, 50) and include age and comorbidity (50),
smoking status (51), tumor location (52), systemic therapy (53,
54) and target therapies (18). The risk of RILI can also be affected
by dose-dependent factors related to the irradiation of the heart
rather than lung (55). Development of multi-factorial models
including clinical and dosimetric factors for prediction of risk of
RILI is important. Such a model was developed using a physician
assessed dyspnea score (CTCAE version 3.0 (14)) as the endpoint
(56). Addition of clinical factors to dosimetric factors improved
the performance of the model in predicting for severe dyspnea
post-RT. The use of patient-scored dyspnea assessments may
further improve the performance of such models. However, these
are only appropriate at doses close to or beyond conventional
accepted tolerance limits and do not provide information on the
effect of radiation at doses below tolerance limits.
In conclusion, dyspnea is a prominent symptom of RILI,
which remains an important limitation for radical treatment of
NSCLC with RT. Monitoring changes in dyspnea as an endpoint
for multi-factorial predictive models of lung toxicity is important
to increase the efficacy of radio(chemo)therapy without
compromising treatment safety. Given the subjective nature of
the symptom, patient-completed tools may be more sensitive and
subject to less bias than physician grading. We have
demonstrated that lung dose-volume parameters predict for a
10% worsening of dyspnea QoL at 3 months and dyspnea VAS at
6 months post-RT. A constraint of 11% of the lung volume
receiving 40 Gy, if validated, may be useful in limiting the
proportion of patients who experience ≥10% increase in
dyspnea score following conventional RT. Further estimates,
including competing risk analysis, will be needed to define the
complex relationship among dyspnea, lung cancer and RILI in
detail, also taking into account the rate of locally advanced
disease stage. Our findings support the use of subjective
dyspnea tools in future studies on lung RT toxicity.DATA AVAILABILITY STATEMENT
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